profit from every €100 of sales.
€0€100
bioMérieux
€92.30+0.11% today
-16.8% since Dec 22, 25
1-year low €66.601-year high €114.80
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €27.39 for every €1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What bioMérieux sold, what it kept, and what it did with the cash.
Sales went from €3.59 billion in 2022 to €4.07 billion in 2025, with €398 million of profit last year.
SalesProfit
bioMérieux handed back 23% of the cash it generated last year.
€106M
Free cash flow 2025€453M
Bought back its own shares–
Paid as dividends€106M
Cash vs. debt€570M vs. €461M
bioMérieux vs. similar companies
bioMérieux grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| bioMérieux | 27.4× · Fair price | ||
 Thermo Fisher Scientific | 38.7× · Expensive | ||
 Danaher | 45.2× · Expensive | ||
 Waters | 141.4× · Very expensive | ||
 WuXi AppTec | 27.1× · Fair price |
AI analysis
An AI analyst reads bioMérieux's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3,589 | 3,675 | 3,980 | 4,070 | |
| 2,009 | 2,057 | 2,215 | 2,309 | |
| 626 | 569 | 638 | 695 | |
| 833 | 712 | 898 | 849 | |
| 452 | 358 | 432 | 398 | |
| 3.82 | 3.01 | 3.64 | – | |
| 56.0% | 56.0% | 55.7% | 56.7% | |
| 17.4% | 15.5% | 16.0% | 17.1% | |
| 12.6% | 9.7% | 10.9% | 9.8% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 5,187 | 5,259 | 5,770 | 5,575 |
| Cash | 553 | 352 | 450 | 570 |
| Total debt | 505 | 519 | 490 | 461 |
| Total liabilities | 1,544 | 1,507 | 1,559 | 1,469 |
| 3,604 | 3,752 | 4,205 | 4,102 | |
| 118 | 119 | 119 | – | |
| 10.7% | 8.0% | 9.5% | 8.9% | |
| 12.6% | 9.5% | 10.3% | 9.7% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 475 | 445 | 667 | 788 | |
| 287 | 338 | 346 | 335 | |
| 188 | 107 | 322 | 453 | |
| Dividends paid | 101 | 100 | 100 | 106 |
| 157 | – | – | – | |
| 13 | 20 | 23 | 27 |
Valuation
- 27.4×
- –
- –
- 2.0×
- 2.7×
- 24.0×
- 12.7×
- 4.2%
- 3.7%
- 1.0%
Profitability
- 56.7%
- 17.1%
- 9.8%
- –
- 8.9%
- 9.3%
- –
- –
- –
- –
Growth
- +4.3%
- –
- –
- –
- −0.0%
Financial health
- -0.1×
- 0.11
- –
- 34.3×
- 2.39
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 35%of 952
Top 30%of 883
Top 49%of 576
Bottom 25%of 870
Top 27%of 985
1.0%of the share price, paid each year
On $1,000 invested$10a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
26.7% of its profit
Room to growStretchedMore than it earns: 23.4%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
65Pass
Benjamin Graham
62Pass
Philip Fisher
51No pass
Peter Lynch
52No pass
Joel Greenblatt
24No pass
Charlie Munger
53No pass
Terry Smith
50No pass
Questions about bioMérieux
Is bioMérieux a good stock to buy?
A solid business at a fair price. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the bioMérieux AI analysis
What does bioMérieux do?
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It is in Diagnostics & Research, based in Marcy-l'Étoile, France, with 14,562 employees.
Does bioMérieux pay a dividend?
Yes. At today's price the dividend is 1.0% a year, about 27% of its yearly profit. In 2025 it paid out €106 million in dividends.
Is bioMérieux stock halal?
Yes. bioMérieux passes our halal screen: its business is permitted and its debt is 4% of its market value, under the 30% limit. How we check
Who are bioMérieux's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, Waters and WuXi AppTec. The peers table on this page compares their profit, growth and price with bioMérieux's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.